Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Non-Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial

International Journal of Radiation Oncology Biology Physics

Volumn 73, Issue 4, 2009, Pages 1069-1076

  Mehta, Minesh P ^a   Shapiro, William R ^b   Phan, See C ^c   Gervais, Radj ^d   Carrie, Christian ^e   Chabot, Pierre ^f   Patchell, Roy A ^g   Glantz, Michael J ^h   Recht, Lawrence ⁱ   Langer, Corey ^j   Sur, Ranjan K ^k   Roa, Wilson H ^l   Mahe, Marc A ^m   Fortin, Andre ⁿ   Nieder, Carsten ^o   Meyers, Christina A ^p   Smith, Jennifer A ^c   Miller, Richard A ^c   Renschler, Markus F ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

^c Pharmacyclics   (United States)

^d CENTRE FRANÇOIS BACLESSE   (France)

^e CENTRE LÉON BÉRARD   (France)

^f MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^g UNIVERSITY OF KENTUCKY   (United States)

^h UNIVERSITY OF MASSACHUSETTS   (United States)

ⁱ STANFORD UNIVERSITY   (United States)

^j FOX CHASE CANCER CENTER   (United States)

^k JURAVINSKI CANCER CENTRE   (Canada)

^l CROSS CANCER INSTITUTE   (Canada)

^m CENTRE RENÉ GAUDUCHEAU   (France)

ⁿ LAVAL UNIVERSITY   (Canada)

^o TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^p UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Brain metastases; Motexafin gadolinium; Neurocognitive function; Neurologic progression; Non small cell lung cancer; Whole brain radiotherapy

Indexed keywords

BRAIN; GADOLINIUM; PATHOLOGY; RADIOTHERAPY;

BRAIN METASTASES; MOTEXAFIN GADOLINIUM; NEUROCOGNITIVE FUNCTION; NEUROLOGIC PROGRESSION; NON-SMALL-CELL LUNG CANCER; WHOLE BRAIN RADIOTHERAPY;

DRUG PRODUCTS;

GADOLINIUM TEXAPHYRIN;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BLISTER; BRAIN METASTASIS; BRAIN RADIATION; BRAIN SURGERY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CHROMATURIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL PAIN; HUMAN; HYPERTENSION; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MUSCLE WEAKNESS; NAUSEA AND VOMITING; NEUROLOGICAL COMPLICATION; OUTCOME ASSESSMENT; PAIN; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOSURGERY; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SCLERA; SIDE EFFECT; SKIN DISCOLORATION; THERAPY DELAY; THERAPY EFFECT; URINE COLOR; WHOLE BRAIN RADIOTHERAPY;

AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COGNITION DISORDERS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; FEMALE; HUMANS; LUNG NEOPLASMS; METALLOPORPHYRINS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS;

EID: 61549104698     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.05.068     Document Type: Article

References (19)

1. Langer C.J., and Mehta M.P. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23 (2005) 1-13
2. Posner J.B. Neurologic complications of cancer (1995), FA Davis, Philadelphia p. 4-5
3. Mehta M.P., Shapiro W.R., Glantz M.J., et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 20 (2002) 3445-3453
4. Mehta M.P., Rodrigus P., Terhaard C., et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21 (2003) 2529-2536
5. Meyers C.A., Smith J.A., Bezjak A., et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial. J Clin Oncol 22 (2004) 157-165
6. Shapiro W.R., Smith J.A., Patchell R.A., et al. Validation of blinded Events Review Committee (ERC)-determined time to neurologic progression (TTNP) demonstrates correlation with survival, radiologic progression, and functional independence endpoints. [Abstract]. J Clin Oncol 23 (2005) 122s
7. Lecane P., Karaman M.W., Sirisawad M., et al. Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res 65 (2005) 1-13
8. Magda D., Lecane P., Miller R.A., et al. Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. Cancer Res 65 (2005) 3837-3845
9. Hashemy S.I., Ungerstedt J.S., Avval F.Z., et al. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase and ribonucleotide reducatase. J Biol Chem 281 (2006) 10691-10697
10. Kakolyris S., Giatromanolaki A., Koukourakis M., et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 7 (2001) 3087-3091
11. Rosenthal D.I., Nurenberg P., Becerra C.R., et al. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 5 (1999) 739-745
12. Viala J., Vanel D., Meingan P., et al. Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: Preliminary results in brain metastases. Radiology 212 (1999) 755-759
13. Carde P., Timmerman R., Mehta M.P., et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 19 (2001) 2074-2083
14. Xu S., Zakian K., Thaler H., et al. Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int J Radiat Oncol Biol Phys 49 (2001) 1381-1390
15. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Org 79 (2001) 373-374
16. Wei L.J., and Lachin J.M. Properties of the urn randomization in clinical trials [published erratum appears in Control Clin Trials 1989;10; following 126]. Control Clin Trials 9 (1988) 345-364
17. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
18. Halfdanarson T.R., Hogan W.J., and Moynihan T.J. Oncologic emergencies: Diagnosis and treatment. Mayo Clin Proc 81 (2006) 835-848
19. Robinet G., Thomas P., Breton J.L., et al. Result of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol 12 (2001) 59-67